Search En menu ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 20,000,000
    Countries
    Sector(s)
    Ireland : € 10,000,000
    Germany : € 10,000,000
    Industry : € 20,000,000
    Signature date(s)
    1/12/2016 : € 5,000,000
    1/12/2016 : € 5,000,000
    1/12/2016 : € 5,000,000
    1/12/2016 : € 5,000,000

    Summary sheet

    Release date
    15 December 2016
    Status
    Reference
    Signed | 01/12/2016
    20160461
    Project name
    Promoter - financial intermediary
    AMRYT PHARMA (EGFF)
    AMRYT PHARMACEUTICALS DAC
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 20 million
    EUR 46 million
    Location
    Sector(s)
    Description
    Objectives

    This project will finance the research and development (R&D) investment and growth of Amryt Group. Amryt Group is an orphan disease speciality pharmaceutical company which may be characterised by medium to high growth and very high research and development (R&D) intensity. The company is focusing on bringing innovative orphan drugs to the market, addressing clearly identified high unmet medical needs, and helping increase the quality of life of patients suffering from rare diseases. The R&D intensity of the company is reflected in the active drug development activity and also the fact that it already owns four patent families covering Europe, the US and other major markets (e.g. Japan, Australia, China).

    The scope of the company's research, development and innovation (RDI) investments is in line with the priority areas of Horizon 2020 (Health, Demographic Change and Wellbeing). Furthermore, it addresses a constant demand for novel treatments also for people suffering from rare diseases. In addition, positive externalities would derive from the development of novel drugs contributing to the increase in quality of life mainly through pain reduction.

    Environmental aspects
    Procurement

    The promoter's investments concern research, development and innovation activities as well as production deployment that will be in large part carried out in existing facilities already authorised for similar activities and volumes and that do not require an environmental impact assessment (EIA) according to the relevant EU directives.

    The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by the EU directives on procurement.

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    scoreboard - EUROPEAN GROWTH FINANCE FACILITY
    Publication Date
    13 Sep 2019
    Document Language
    English
    Main Topic
    lending
    Document Number
    122912044
    Document Focus
    EFSI legal requirements
    Document Type
    Scoreboard
    Project Number
    20170859
    Last update
    19 Aug 2020
    Sector(s)
    Industry
    Publicly available
    Download now

    News & Stories

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications